Introduction
Uncomplicated gonorrhoea is very frequent among young adults in Kigali, capital of Rwanda, Central Africa. At the Centre Medico-Social de Bilyogo (CMS), Nyamirambo, Kigali, about 1500 new cases of gonococcal urethritis and cervicitis are diagnosed yearly. The CMS is a primary health care centre situated 3 km from the laboratory of the Centre Hospitalier de Kigali (CHK), the only laboratory performing bacteriological cultures in the city and the prefecture of Kigali (population of 1,4000,000).
In 1985, a single oral dose of 800 mg of norfloxacin cured 97.5% of patients in Kigali, and was significantly more effective than a single oral dose of 2.5 g of thiamphenicol.' Because of the widespread existence of Neisseria gonorrhoeae resistant to penicillin, tetracycline and thiamphenicol, norfloxacin was selected as first line treatment of uncomplicated gonorrhoea in men and non-pregnant women, presenting at the CMS of Bilyogo. Norfloxacin is less expensive than both spectinomycin and cefotaxime, the only third generation cephalosporin available in Rwanda, and can be given by mouth. In 1989, it was replaced by ofloxacin because of a shortage in the supply of norfloxacin.
We present here results of monitoring the efficacy of quinolones for the treatment of uncomplicated gonorrhoea, as well as the antimicrobial susceptibility patterns of gonococcal isolates over time in Kigali. These results confirm that strains, relatively resistant to one quinolone, have also decreased susceptibility to other members of the group,2 3 and that even limited use of quinolones in a community fairly rapidly leads to a gradual development of antimicrobial resistance. The studies also suggest that decreasing in vitro susceptibility of N gonorrhoeae, at least to norfloxacin, is associated with a decreasing therapeutic efficacy of the quinolones. Therefore, it is of utmost public health importance that the in vitro susceptibility and/or therapeutic efficacy of quinolones be closely monitored when these are recommended and used for the treatment of gonorrhoea in a country.
Materials and methods
In spite of the absence of signs or symptoms of urethritis, seven (3.6%) out of 197 clinically cured patients from both treatment regimens had still a positive gonococcal culture at 3 to 7 days after therapy. The [14] [15] [16] [17] [18] In addition, the high prevalence of the human immunodeficiency virus (HIV) in Central Africa, especially in patients with sexually transmitted diseases, makes oral therapy preferable over parenteral administration of drugs to decrease the risk of parenteral transmission of HIV. Finally, from a public health point of view it seems desirable that a highly effective treatment regimen for gonorrhoea be used, even if such a drug is slightly more expensive than less effective alternatives such as the now widely used kanamycin. Such an approach should benefit both the patient (by reducing the risk of complications) and the community (by slowing down the development of antimicrobial resistance and by decreasing the duration of infectivity of patients which reduces the transmission of gonorrhoea).
Despite the problems mentioned above, quinolones are now indicated as a first line treatment of gonorrhoea in countries with a problem of antimicrobial multiresistance, provided that the antimicrobial susceptibility of N. gonorrhoeae and clinical effectiveness of the quinolones be closely monitored.
